Boston Scientific (BSX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this medical device manufacturer have returned -21.7%, compared to the Zacks S&P 500 composite's -0.3% change. During this period, the Zacks Medical - Products industry, which Boston Scientific falls in, has lost 0.4%. The key question now is: What could be the stock's future directio ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB:BSXGF) is pleased to announce that it has closed its non-brokered private placement financing for gross proceeds of US$30 million (C$41.3 million) (the “Private Placement”), as previously announced on December 22, 2025. Pursuant to the closing of the Private Placement, the Company issued a total of 96,146 ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Boston Scientific and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the ...

New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE:BSX) concerning potential violations of the federal securities laws.On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, appro ...

Core Insights - Boston Scientific (BSX) and Abbott (ABT) are prominent players in the U.S. MedTech sector, attracting significant investor interest due to their diversified business models and innovative product offerings [1][2] Boston Scientific Overview - Boston Scientific's operational sales grew by 14% year over year in Q4 2025, exceeding the Zacks Consensus Estimate by 2.6% [3] - The company anticipates a return to market growth in Urology in 2026, driven by new product launches and the sacral neuromodulation franchise [3] - The acquisition of Valencia is expected to enhance Boston Scientific's pelvic health portfolio [3] - Neuromodulation performance is bolstered by strong brain and pain franchises, with the Nalu acquisition expanding into peripheral nerve pain [4] - The Interventional Cardiology Therapies segment is benefiting from the AGENT Drug-Coated Balloon, with plans to expand indications for SEISMIQ IVL [5] - WATCHMAN sales increased by 29% year over year in Q4, supported by strong adoption rates [6] - Boston Scientific's adjusted gross and operating margins expanded by 30 and 100 basis points, respectively, despite challenges from product discontinuations [7] Abbott Overview - Abbott's Q4 2025 sales rose by 4.4% year over year but fell short of the Zacks Consensus Estimate by 2.8% [8] - The company is transitioning to a volume-driven business model in Nutrition, with plans to introduce at least eight new products in the next 12 months [8] - Abbott's Established Pharmaceuticals business is benefiting from high-demand therapeutic areas and advancing its biosimilar strategy in emerging markets [9] - The FreeStyle Libre CGM system achieved over $7.5 billion in sales in 2025, marking three consecutive years of over $1 billion in annual revenues [10] - Abbott's Medical Devices segment achieved several milestones, including regulatory approvals and national coverage for key products [11] - The acquisition of Exact Sciences is a strategic move to expand into cancer diagnostics [12] Financial Estimates and Performance - The consensus estimate for Boston Scientific's 2025 EPS is $3.46, reflecting a 13.1% year-over-year increase [13] - Abbott's consensus estimate for 2026 EPS is $5.68, indicating a 10.3% improvement over 2025 [15] - Over the past six months, Boston Scientific shares have declined by 27.9%, while Abbott shares have decreased by 15% [16] - Boston Scientific is trading at a forward five-year Price/Sales (P/S) ratio of 4.96, while Abbott's is at 4.05 [16] Investment Considerations - Both companies are taking strategic actions to enhance long-term growth prospects, with Boston Scientific showing strong performance in key business units [18] - Abbott's recent performance reflects broad-based growth, particularly in Electrophysiology and CGM [20] - Analysts are optimistic about both companies, with rising earnings estimates, but Abbott appears more attractive in terms of valuation and recent performance [20]

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws following its fourth-quarter 2025 earnings report, which revealed a significant shortfall in its electrophysiology segment sales compared to market expectations [1][5]. Financial Performance - Boston Scientific reported fourth-quarter 2025 earnings, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales were $890 million, which was approximately $43 million below the consensus estimate of $933 million [2]. - The company had previously guided for organic growth of 11% to 13% for Q4 2025, but management indicated confidence in only about 15% growth going forward, creating a notable gap between market expectations and internal projections [4][5]. Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology potentially replacing traditional thermal ablation procedures [3]. - Boston Scientific entered this market through the acquisition of Farapulse in 2021 and has made significant investments in expanding manufacturing capacity and physician training programs [3]. Growth Projections - The company projected that global penetration of pulsed field ablation technology would reach 50% by the end of 2025 and grow to approximately 80% by 2028 [3]. - The company emphasized strong growth rates in its electrophysiology segment, reporting 94% growth in Q2 2025 and 63% growth in Q3 2025 [4].

Core Viewpoint - The article suggests that sometimes the best investment opportunities come from established winners that are poised for another growth cycle [1] Group 1 - The focus is on identifying old successful ideas that may be ready for renewed interest and investment [1]

Financial Performance - Reported net sales for Boston Scientific in 2025 reached $20,074 million, a 19.9% increase from $16,747 million in 2024[166] - Reported net income attributable to common stockholders in 2025 was $2,898 million, reflecting a 56.4% increase from $1,853 million in 2024[166] - Adjusted net income attributable to common stockholders for 2025 was $4,574 million, up 22.8% from $3,725 million in 2024[166] - Organic net sales growth for 2025 was 15.8%, compared to 16.4% in 2024, indicating strong underlying performance despite external challenges[166] - Gross profit for 2025 was $13.854 billion, with a gross profit margin of 69.0%, down from 68.6% in 2024 and 69.5% in 2023[178][179] - Reported net income for the year ended December 31, 2025, was $3,385 million, with adjusted net income of $5,182 million, reflecting a per share impact of $3.06[256] Business Unit Performance - The Cardiovascular business unit saw a reported net sales growth of 23.2% in 2025, driven by the Farapulse™ Pulsed Field Ablation System and other coronary therapies[176] - The Urology business reported a 23.1% increase in net sales in 2025, primarily due to the acquisition of Axonics and growth in the stone management franchise[174] - Emerging Markets contributed to net sales growth, particularly in China, with reported sales growth of 11.4% in 2025[177] Expenses and Charges - SG&A expenses increased by $903 million, or 15%, in 2025 compared to 2024, representing 34.3% of net sales[182] - R&D expenses rose by $436 million, or 27%, in 2025 compared to 2024, accounting for 10.2% of net sales[183] - Restructuring charges for 2025 totaled $101 million, with restructuring-related net charges of $242 million[190] - The company incurred restructuring charges related to the discontinuation of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems in 2025[252] Cash Flow and Debt - Cash provided by operating activities increased by $1.100 billion in 2025 compared to 2024, driven by higher net sales and operating income[211] - Cash used for investing activities in 2025 included net cash payments of $1.593 billion for acquisitions and $876 million for property, plant, and equipment[212] - Total debt as of December 31, 2025, was $11.436 billion, with $11.137 billion classified as long-term debt[219] - The company was in compliance with the financial covenant of a maximum permitted leverage ratio of 4.50 times, with an actual ratio of 1.92 times as of December 31, 2025[216][217] Acquisitions and Investments - The company completed the acquisition of Nalu Medical for approximately $517 million on January 27, 2026, integrating it into the Neuromodulation division[208] - The company announced a definitive agreement to acquire Penumbra for approximately $14.500 billion, expected to be completed in 2026, funded by $11.000 billion in new debt and cash on hand[209] - The company completed the acquisitions of Bolt Medical and SoniVie for purchase prices of $782 million and $516 million, respectively, during 2025[283] Tax and Legal Matters - The reported tax rate for 2025 was 14.6%, down from 19.1% in 2024, with a rate from continuing operations of 18.9%[197] - The company recorded litigation-related net charges of $194 million in 2025 related to a legacy IP matter[192] Currency and Risk Management - The impact of foreign currency fluctuations on reported net sales was a decrease of 0.7% in 2025, compared to an increase of 0.9% in 2024[166] - The company had currency derivative instruments outstanding with a contract amount of $12.726 billion as of December 31, 2025, compared to $7.636 billion as of December 31, 2024[274] - A 10% appreciation in the U.S. dollar relative to hedged currencies would increase the fair value of derivative instruments by $804 million as of December 31, 2025[274] Internal Controls and Compliance - The company maintained effective internal control over financial reporting as of December 31, 2025, according to an unqualified opinion from Ernst & Young LLP[264] - The company’s internal control assessment excluded the internal controls of the newly acquired businesses for up to one year from the acquisition date[265]

Core Viewpoint - Belo Sun Mining Corp. has successfully reinstated its Installation License for the Volta Grande Gold Project in Brazil, allowing the company to resume construction activities after a suspension since 2017 [1][3][6]. Background - The Federal Court of Altamira had previously upheld the suspension of the Installation License, prompting the company to take legal action to challenge this decision [2]. Court of Appeal Decision - On February 13, 2026, the Federal Regional Court granted interim relief, reinstating the Installation License and permitting Belo Sun to continue installation activities for the Project [3]. Compliance and Consultation - The Court determined that the company had met all conditions set by TRF-1, including the preparation of the Indigenous Component Study based on primary data and conducting consultations with local Indigenous communities in accordance with established protocols [4]. - The Court also ruled that FUNAI's reversal of its earlier position regarding the sufficiency of the ECI was not supported by formal administrative procedures, requiring any new requirements to follow proper technical justification [5]. Construction Activities - With the ruling, the Installation License is now fully effective, allowing the company to proceed with construction and installation activities for the Project [6]. Next Steps - The respondents to the appeal have the opportunity to file a response, and the appeal will be reviewed by the 6th Panel of TRF-1, with further updates to be provided by the company [7]. Company Leadership Comments - The Chairman and CEO of Belo Sun expressed gratitude for the support received from local communities and authorities, highlighting the significance of this milestone for the company and its stakeholders [8][9]. Project Development Commitment - The company aims to develop the project in line with best international mining practices, focusing on environmental protection and social standards to contribute to the region's economic development [10].

Core Insights - Boston Scientific (BSX) reported strong fourth-quarter results for 2025, exceeding both revenue and earnings guidance, with over $20 billion in sales and 12.7% organic revenue growth [1][8] - The company faced challenges in Urology due to supply-chain issues and competitive pressures in Electrophysiology, leading to a 17.6% drop in stock price post-earnings announcement [2][3] Financial Performance - Boston Scientific achieved mid-teens growth for the second consecutive year, attributed to innovation and execution across business units [1] - The company expects organic growth of 10%-11% for 2026, despite near-term challenges [9][12] Segment Highlights - WATCHMAN business grew 29% year-over-year in Q4, supported by strong adoption in U.S. procedures and a strategic partnership with Siemens Healthineers [4] - Neuromodulation sales increased by 10% in Q4, with a full-year organic growth of 8%, bolstered by new product offerings and expanded reimbursement coverage [5] - APAC region sales surged 15% operationally in Q4, driven by strong performances in Japan and China [6] Market Position and Challenges - Boston Scientific holds approximately 65% market share in the PFA market, with expectations to exceed the 15% market growth rate despite competitive pressures [10] - The company announced acquisitions of Valencia Technologies and Penumbra to enhance its urology and cardiovascular capabilities [11] Profitability Outlook - Adjusted gross margin is expected to remain stable, with operating margin projected to expand by 50-75 basis points, and adjusted EPS anticipated to grow by 12%-14% [12] - First-quarter 2026 revenue growth is guided at 8.5%-10%, facing challenges from product discontinuations [13] Valuation Metrics - Boston Scientific trades at a forward Price/Sales (P/S) ratio of 4.87, which is below its historical median but above the industry average of 2.67 [17] Conclusion - Despite recent stock performance challenges, Boston Scientific's strong fundamentals and growth potential in key segments suggest a prudent hold for investors, with an attractive valuation relative to competitors [18]